EGFR and neoplasm: In NSCLC, mutation or overexpression of EGFR promotes immunosuppression, and the inhibition of EGFR using gefitinib or erlotinib can restore MHC class I expression, reduce PD-L1 expression or upregulate the expression of NKG2D ligands for NK cell-mediated tumor killing [107].